calcium;(3R,5R)-7-[2-(4-fluorophenyl)-3-phenyl-4-(phenylcarbamoyl)-5-propan-2-ylpyrrol-1-yl]-3,5-dihydroxyheptanoate;(3R,5R)-7-[2-(4-fluorophenyl)-3-phenyl-4-(phenylcarbamoyl)-5-propan-2-ylpyrrol-1-yl]-3-hydroperoxy-5-hydroxyheptanoate

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯
• 英文名称: calcium;(3R,5R)-7-[2-(4-fluorophenyl)-3-phenyl-4-(phenylcarbamoyl)-5-propan-2-ylpyrrol-1-yl]-3,5-dihydroxyheptanoate;(3R,5R)-7-[2-(4-fluorophenyl)-3-phenyl-4-(phenylcarbamoyl)-5-propan-2-ylpyrrol-1-yl]-3-hydroperoxy-5-hydroxyheptanoate
• 化学式: C66H68CaF2N4O11
• 分子量: 1171.3
• InChiKey: HCLIDJNBTHESJL-MNSAWQCASA-L

计算性质

• 辛醇/水分配系数(LogP)：
  10.07
• 重原子数：
  84
• 可旋转键数：
  23
• 环数：
  8.0
• sp3杂化的碳原子比例：
  0.27
• 拓扑面积：
  239
• 氢给体数：
  6
• 氢受体数：
  13

文献信息

• Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids
  申请人：Amarin Pharmaceuticals Ireland Limited

  公开号：US10172818B2

  公开（公告）日：2019-01-08

  In various embodiments, the present invention provides methods of treating and/or preventing cardiovascular-related disease and, in particular, a method of reducing or preventing small dense LDL (“sdLDL”) oxidation in a subject, the method comprising administering to the subject a pharmaceutical composition comprising eicosapentaenoic acid or a derivative thereof.

  在各种实施方案中，本发明提供了治疗和/或预防心血管相关疾病的方法，特别是减少或预防受试者体内小密度低密度脂蛋白（"sdLDL"）氧化的方法，该方法包括向受试者施用包含二十碳五烯酸或其衍生物的药物组合物。
• Methods of reducing or preventing oxidation of small dense ldl or membrane polyunsaturated fatty acids
  申请人：Amarin Pharmaceuticals Ireland Limited

  公开号：US10842765B2

  公开（公告）日：2020-11-24

  In various embodiments, the present invention provides methods of treating and/or preventing cardiovascular-related disease and, in particular, a method of reducing or preventing sdLDL oxidation in a subject, the method comprising administering to the subject a pharmaceutical composition comprising eicosapentaenoic acid or a derivative thereof.

  在各种实施方案中，本发明提供了治疗和/或预防心血管相关疾病的方法，特别是减少或预防受试者 sdLDL 氧化的方法，该方法包括向受试者施用包含二十碳五烯酸或其衍生物的药物组合物。
• PHARMACEUTICAL COMPOSITION COMPRISING OMEGA-3 FATTY ACID AND HYDROXY-DERIVATIVE OF A STATIN AND METHODS OF USING SAME
  申请人：Amarin Pharmaceuticals Ireland Limited

  公开号：EP2480248B1

  公开（公告）日：2015-09-02
• PHARMACEUTICAL COMPOSITION COMPRISING AN OMEGA-3 FATTY ACID AND A HYDROXY-DERIVATIVE OF A STATIN AND METHODS OF USING SAME
  申请人：Amarin Pharmaceuticals Ireland Limited

  公开号：US20140080850A1

  公开（公告）日：2014-03-20

  In various embodiments, the present invention provides compositions and methods for treating and/or preventing a cardiovascular-related disease in subject in need thereof.
• METHODS OF REDUCING OR PREVENTING OXIDATION OF SMALL DENSE LDL OR MEMBRANE POLYUNSATURATED FATTY ACIDS
  申请人：MASON Richard Preston

  公开号：US20170087111A1

  公开（公告）日：2017-03-30

  In various embodiments, the present invention provides methods of treating and/or preventing cardiovascular-related disease and, in particular, a method of reducing or preventing small dense LDL (“sdLDL”) oxidation in a subject, the method comprising administering to the subject a pharmaceutical composition comprising eicosapentaenoic acid or a derivative thereof.